The Progress of Gene Therapy for Leber's Optic Hereditary Neuropathy

Curr Gene Ther. 2017;17(4):320-326. doi: 10.2174/1566523218666171129204926.

Abstract

Introduction: Leber's Optic Hereditary Neuropathy (LHON) is a common cause of teenaged blindness in both eyes for which there is currently no effective treatment. In 1871, the German ophthalmologist Theodor Leber was the first to describe the clinical characteristics of his namesake disease, and through unremitting efforts over the past 100 years, researchers have continued to increase their understanding of LHON. In recent years, using gene therapy, several groups have obtained breakthroughs in the treatment of the disease.

Conclusion: In this article, we will review the challenging journey that researchers faced towards our current understanding of LHON, and describe the transition of gene therapy research for LHON from the bench to bedside.

Keywords: Allotopic expression technology; Gene therapy; Leber's optic hereditary neuropathy; MT-ND4; Mitochondrial disease; Translational medicine.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • DNA, Mitochondrial / genetics
  • Genetic Predisposition to Disease / genetics
  • Genetic Therapy / methods*
  • Genetic Therapy / trends
  • Humans
  • Mutation
  • NADH Dehydrogenase / genetics
  • NADH Dehydrogenase / metabolism
  • Optic Atrophy, Hereditary, Leber / genetics
  • Optic Atrophy, Hereditary, Leber / therapy*
  • Translational Research, Biomedical / methods*
  • Translational Research, Biomedical / trends

Substances

  • DNA, Mitochondrial
  • NADH dehydrogenase subunit 4
  • NADH Dehydrogenase